NCT02354508 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 123
- units
- Participants
- groups
- description
- Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).
- id
- BG000
- title
- Lanreotide 120 mg
- description
- Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .
- id
- BG001
- title
- Octreotide 30 mg
- description
- Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).
- id
- BG002
- title
- Octreotide 40 mg
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.02
- value
- 41.8
- group Id
- BG001
- spread
- 12.89
- value
- 41.6
- group Id
- BG002
- spread
- 11.63
- value
- 46.6
- group Id
- BG003
- spread
- 11.60
- value
- 43.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 62
- title
- Female
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 61
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 78
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 30
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS): comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 123
- units
- Participants
- groups
- description
- Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).
- id
- BG000
- title
- Lanreotide 120 mg
- description
- Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .
- id
- BG001
- title
- Octreotide 30 mg
- description
- Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).
- id
- BG002
- title
- Octreotide 40 mg
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.02
- value
- 41.8
- group Id
- BG001
- spread
- 12.89
- value
- 41.6
- group Id
- BG002
- spread
- 11.63
- value
- 46.6
- group Id
- BG003
- spread
- 11.60
- value
- 43.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 62
- title
- Female
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 61
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 78
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 30
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS): comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle